INTRODUCTION

Durvalumab (brand name Imfinzi) is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to the protein programmed cell death ligand 1 (PD-L1) to promote normal immune responses that kill cancer cells. Durvalumab is an immune checkpoint inhibitor drug used to treat different types of cancer such as urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.

This plasmid is designed for expressing Durvalumab in mammalian Chinese Hamster Ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-64
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Durvalumab
Brand Name(s): Imfinzi
Classification: Monoclonal antibody (mAb)
Target: programmed cell death ligand 1 (PD-L1), CD274, B7-H, B7H1, PDL1, PD-L1, hPD-L1, PDCD1L1, PDCD1LG1
Action Type: Inhibitor, antagonist
Amino Acid Sequence: Identical to DB11714

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Botticella A, Mezquita L, Le Pechoux C, Planchard D. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885530.

[2] Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017 Jul 17;7(1):5532.

Contact Us